Cyclerion Therapeutics (NASDAQ:CYCN – Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($17.20) by $16.44, Zacks reports. Cyclerion Therapeutics had a negative net margin of 170.11% and a negative return on equity of 39.23%.
Cyclerion Therapeutics Price Performance
Shares of Cyclerion Therapeutics stock traded down $0.01 during trading on Tuesday, hitting $3.18. 55,542 shares of the company’s stock traded hands, compared to its average volume of 4,212,205. Cyclerion Therapeutics has a 1 year low of $1.03 and a 1 year high of $8.48. The business has a 50-day simple moving average of $2.55 and a 200-day simple moving average of $1.87. The stock has a market capitalization of $13.77 million, a P/E ratio of -2.74 and a beta of 1.80.
Analyst Ratings Changes
Separately, Weiss Ratings upgraded shares of Cyclerion Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, April 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Two Sigma Investments LP purchased a new stake in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned 0.40% of Cyclerion Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 75.62% of the company’s stock.
About Cyclerion Therapeutics
Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.
The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.
Read More
- Five stocks we like better than Cyclerion Therapeutics
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
